high. Under current doctrine, a generic drugmaker is liable for induced infringement if its drug label so much as hints at … generic drug labels and in cases when only an in-depth inquiry into the language of the label might promote infringement. As I … because it unconstitutionally prolongs drug monopolies and undermines a key statutory path to generic competition. Revisiting …

In this paper, we argue that lower prices for pharmaceuticals can be achieved by fostering a new type of competition in … the pharmaceutical industry. Lower drug development costs, and hence prices, can be brought about by abolishing national … drug administrations and replacing them with private certification boards that compete on the basis of safety, efficiency …

Before a new drug can be marketed the Food and Drug Administration must be satisfied that it is safe and effective … been advocated. This paper challenges the central argument in the debate on the topic, namely that drug regulation and drug … innovation are necessarily at odds with each other. Although intuitively appealing, the argument that drug regulation negatively …

of new drug patents using two quasi-experimental approaches: one based on changes in patent laws and another on the … of new drug development, generic entry, and patent length and scope. Optimal policy calls for shorter but broader …

Background: Rising cancer drug prices pose a challenge for patients and healthcare systems in the US. Whilst prices are … routinely assigned to a drug’s original indication receiving US Food and Drug Administration (FDA) approval, the influence of … drug prices, distinctly analyzing original and supplemental indications.Data and Methods: Clinical trial evidence …